David Braun, MD, PhD

David Braun, MD, PhD, is an assistant professor of medicine and a principal investigator at the Center of Molecular and Cellular Oncology at Yale Cancer Center.

Articles by David Braun, MD, PhD

David Braun, MD, PhDAdvanced Renal Cell Carcinoma | March 24, 2025
Drs. Beckermann and Braun reflect on key lessons from the trial, emphasizing the importance of prioritizing driver mutations.
View More
David Braun, MD, PhDAdvanced Renal Cell Carcinoma | March 24, 2025
Drs. Beckermann and Braun break down the selection process for neoantigens in the trial for personalized RCC vaccines.
David Braun, MD, PhDAdvanced Renal Cell Carcinoma | March 24, 2025
Drs. Beckermann and Braun discuss the latter's Nature publication on a personalized neoantigen vaccine for RCC.
Katy Beckermann, MD, PhDRenal Cell Carcinoma | February 25, 2025
Sequencing, novel therapies, and treatment combinations for refractory RCC are examined in part 5 of this discussion.
Katy Beckermann, MD, PhDRenal Cell Carcinoma | February 25, 2025
The panel explores the evolving role of cytoreductive nephrectomy in RCC and how biomarkers shape treatment decisions.
Katy Beckermann, MD, PhDRenal Cell Carcinoma | February 25, 2025
The panel discusses considerations for triplet therapy in RCC, new trial data, and biomarker-driven treatment strategies.
Katy Beckermann, MD, PhDRenal Cell Carcinoma | February 25, 2025
In part 2, the panelists discuss adjuvant therapy for RCC, including biomarkers and optimizing treatment for better outcomes.
Katy Beckermann, MD, PhDRenal Cell Carcinoma | February 25, 2025
Part one of the discussion covers adjuvant therapy in kidney cancer, patient selection, and balancing risks and benefits.
David Braun, MD, PhDAdvanced Renal Cell Carcinoma | August 12, 2024
Dr. Braun shares insights on updates to the NCCN guidelines for RCC, highlighting how they could impact clinical practice.
David Braun, MD, PhDAdvanced Renal Cell Carcinoma | April 22, 2024
Drs. Braun and Beckermann stress the importance of adopting an integrative approach to biomarker-based research in RCC.
David Braun, MD, PhDAdvanced Renal Cell Carcinoma | April 22, 2024
Drs. Braun and Beckermann review JAVELIN Renal 101, focusing on the impact of avelumab and axitinib treatment on RCC.
David Braun, MD, PhDAdvanced Renal Cell Carcinoma | April 22, 2024
Drs. Braun and Beckermann discuss the evolving significance of sarcomatoid histology in guiding treatment decisions for RCC.
David Braun, MD, PhDAdvanced Renal Cell Carcinoma | May 16, 2023
Drs. McKay and Braun wrap up their discussion with comments on which novel therapies hold the most promise in advanced RCC.
David Braun, MD, PhDAdvanced Renal Cell Carcinoma | May 16, 2023
Drs. McKay and Braun share their strategy for strategy for patient selection in the clinic, including first- and second-line.
David Braun, MD, PhDAdvanced Renal Cell Carcinoma | March 11, 2024
Drs. McKay and Braun highlights novel RCC biomarkers being developed, including imaging-, pathology-, and blood-based ones.
David Braun, MD, PhDAdvanced Renal Cell Carcinoma | March 11, 2024
Dr. McKay speaks with Dr. Braun on the current biomarker landscape for RCC and how biomarkers have shaped treatment.
David Braun, MD, PhDAdvanced Renal Cell Carcinoma | February 14, 2023
David Braun, MD, PhD, highlights the available later-line therapy options for RCC, how the therapies are sequenced, and more.